Olinciguat (IW-1701) is a soluble guanylate cyclase stimulator that was in development for sickle cell anemia.[1][2][3] After receiving orphan drug status in 2018[4] and completing a phase II trial, its development for sickle cell anemia was discontinued in 2020.[5]
^Buys, E. S.; Zimmer, D. P.; Chickering, J.; Graul, R.; Chien, Y. T.; Profy, A.; Hadcock, J. R.; Masferrer, J. L.; Milne, G. T. (1 August 2018). "Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential". Nitric Oxide. 78: 72–80. doi:10.1016/j.niox.2018.05.009. ISSN 1089-8603. PMID 29859918. S2CID 44149174.
^Tchernychev, Boris; Li, Huihui; Lee, Sung-Kyun; Gao, Xin; Ramanarasimhaiah, Raghunath; Liu, Guang; Hall, Katherine C.; Bernier, Sylvie G.; Jones, Juli E.; Feil, Susanne; Feil, Robert; Buys, Emmanuel S.; Graul, Regina M.; Frenette, Paul S.; Masferrer, Jaime L. (September 2021). "Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso-occlusion and nephropathy in mouse models of sickle cell disease". British Journal of Pharmacology. 178 (17): 3463–3475. doi:10.1111/bph.15492. ISSN 1476-5381. PMC 8453770. PMID 33864386.
^Zimmer, Daniel P.; Shea, Courtney M.; Tobin, Jenny V.; Tchernychev, Boris; Germano, Peter; Sykes, Kristie; Banijamali, Ali R.; Jacobson, Sarah; Bernier, Sylvie G.; Sarno, Renee; Carvalho, Andrew; Chien, Yueh-tyng; Graul, Regina; Buys, Emmanuel S.; Jones, Juli E.; Wakefield, James D.; Price, Gavrielle M.; Chickering, Jennifer G.; Milne, G. Todd; Currie, Mark G.; Masferrer, Jaime L. (8 April 2020). "Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease". Frontiers in Pharmacology. 11: 419. doi:10.3389/fphar.2020.00419. ISSN 1663-9812. PMC 7156612. PMID 32322204.
^"Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disease". investor.ironwoodpharma.com. Retrieved 8 November 2023.
^PhD, Joana Carvalho (20 October 2020). "Cyclerion Suspends Development of Olinciguat for Sickle Cell Disease". sicklecellanemianews.com. Retrieved 8 November 2023.
Olinciguat (IW-1701) is a soluble guanylate cyclase stimulator that was in development for sickle cell anemia. After receiving orphan drug status in 2018...
in a phase II trial for heart failure with preserved ejection fraction Olinciguat was developed for sickle cell disease but its development was discontinued...